Journal profile · Pharmacology & Pharmacy
Expert Review of Anti-Infective Therapy
ISSN 1478-7210 · eISSN 1744-8336 · Taylor and Francis Ltd. · ENGLAND · Monthly
Expert Review of Anti-Infective Therapy: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 4.67; hybrid open access; median 111 days to acceptance (101 articles, last 24 months); 105 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Expert Review of Anti-Infective Therapy is published by Taylor and Francis Ltd. and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Antibiotic Resistance in Bacteria, Antibiotic Use and Resistance and Antibiotics Pharmacokinetics and Efficacy, together about 23.2% of its articles. Its main subfields are Infectious Diseases. (generated from OpenAlex topic counts and CAS ranking data)
Expert Review of Anti-Infective Therapy (ISSN 1478-7210) provides expert reviews on therapeutics and diagnostics in the treatment of infectious disease. Coverage includes antibiotics, drug resistance, drug therapy, infectious disease medicine, antibacterial, antimicrobial, antifungal and antiviral approaches, and diagnostic tests.
Source: LetPub
Research area (LetPub): Pharmacology & Pharmacy
Main research topics OpenAlex counts of recent articles; shares are approximate
- Antibiotic Resistance in BacteriaBiochemistry, Genetics and Molecular Biology9.6%
- Antibiotic Use and ResistanceImmunology and Microbiology7.4%
- Antibiotics Pharmacokinetics and EfficacyMedicine6.2%
- Pneumonia and Respiratory InfectionsMedicine5.9%
- Antifungal resistance and susceptibilityMedicine5.6%
- Antimicrobial Resistance in StaphylococcusMedicine4.9%
- Hepatitis C virus researchMedicine4.4%
- Bacterial Identification and Susceptibility TestingBiochemistry, Genetics and Molecular Biology4.4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Infectious Diseases | Zone 3 |
| Minor | Microbiology | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: yes
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Infectious Diseases | Zone 3 |
| Minor | Microbiology | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Pharmacology & Pharmacy | Zone 2 |
| Minor | Infectious Diseases | Zone 3 |
| Minor | Microbiology | Zone 3 |
Top journal: noReview journal: yes
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 4.67LetPub ·
- CiteScore 2026-06
- 9.1LetPub ·
- SJR 2026-06
- 1.02LetPub ·
- SNIP 2026-06
- 1.25LetPub ·
- h-index
- 65LetPub ·
- h-index
- 126OpenAlex ·
- i10-index
- 1,802OpenAlex ·
- 2-year mean citedness
- 4.04OpenAlex ·
- Self-citation rate
- 4.3%LetPub ·
- Share of gold OA articles
- 5.69%LetPub ·
Volume
- Articles per year
- 85LetPub ·
Articles by year OpenAlex count · 2,909 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 107 | 34 | 40 |
| 2025 | 105 | 41 | 408 |
| 2024 | 111 | 32 | 856 |
| 2023 | 111 | 44 | 1,706 |
| 2022 | 82 | 23 | 1,331 |
| 2021 | 122 | 51 | 3,050 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
111 daysMedian, submission to acceptance · P25–P75 70 days – 168 days
- Acceptance to online
- median 8 days (101 articles)
- Submission to online
- median 121 days
- Sample
- 101 articles with submission and acceptance dates (231 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 4–8 weeksLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
No source has fee information yet; check the journal's website.
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Taylor and Francis Ltd.
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Monthly
- ISSN
- 1478-7210
- Electronic ISSN
- 1744-8336
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about Expert Review of Anti-Infective Therapy
What CAS zone is Expert Review of Anti-Infective Therapy in?
In the 2025 upgraded edition of the CAS Journal Ranking, Expert Review of Anti-Infective Therapy is in Zone 3 of Medicine, and in Zone 3 of the minor category Infectious Diseases / Microbiology / Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Expert Review of Anti-Infective Therapy?
The latest impact factor listed by LetPub is 4.67; CiteScore 9.1, h-index 126.
How long does peer review take at Expert Review of Anti-Infective Therapy?
Based on the dates recorded on 101 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 111 days (interquartile range 70–168 days); authors report an average review time of 4–8 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Expert Review of Anti-Infective Therapy?
According to LetPub and DOAJ records, Expert Review of Anti-Infective Therapy is indexed in SCIE and Scopus.
Is Expert Review of Anti-Infective Therapy open access, and what is the APC?
Expert Review of Anti-Infective Therapy is a hybrid journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .